The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth

被引：134

作者：

Kertesz, N

Krasnoperov, V

Reddy, R

Leshanski, L

Kumar, SR

Zozulya, S

Gill, PS

机构：

[1] Vasgene Therapeut Inc, Los Angeles, CA 90033 USA

[2] Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA USA

[3] Univ So Calif, Dept Surg, Keck Sch Med, Los Angeles, CA USA

[4] Univ So Calif, Dept Med, Keck Sch Med, Los Angeles, CA USA

来源：

BLOOD | 2006年 / 107卷 / 06期

关键词：

D O I：

10.1182/blood-2005-04-1655

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The receptor tyrosine kinase EphB4 and its ligand EphrinB2 play a crucial role in vascular development during embryogenesis. The soluble monomeric derivative of the extracellular domain of EphB4 (sEphB4) was designed as an antagonist of EphB4/EphrinB2 signaling. sEphB4 blocks activation of EphB4 and EphrinB2; suppresses endothelial cell migration, adhesion, and tube formation in vitro; and inhibits the angiogenic effects of various growth factors (VEGF and bFGF) in vivo. sEphB4 also inhibits tumor growth in murine tumor xenograft models. sEphB4 is thus a therapeutic candidate for vascular proliferative diseases and cancer.

引用

页码：2330 / 2338

页数：9

共 46 条

[1] Molecular control of arterial-venous blood vessel identity [J].